F2

Prothrombin · P00734 · F2 on Sugi Atlas →

311,590 patent compounds predicted against F2, 175,678 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL49000	1.00	20/20
Melagatran (SCHEMBL27652)	0.64	20/20
Dabigatran (SCHEMBL3573)	1.00	19/20
Inogatran (SCHEMBL22745)	0.52	19/20
Inogatran (SCHEMBL22746)	0.52	19/20
Ximelagatran (SCHEMBL4845)	1.00	17/20
Paranyline (SCHEMBL25564)	0.49	13/20
Paranyline (SCHEMBL43643)	0.47	13/20
SCHEMBL49084	0.73	11/20
Bendamustine (SCHEMBL26319)	0.41	9/20
Bendamustine (SCHEMBL18843)	0.41	9/20
Argatroban (SCHEMBL4374)	0.83	7/20
SCHEMBL49594	0.55	7/20
SCHEMBL76968	0.48	6/20
Otamixaban (SCHEMBL52983)	0.81	5/20
SCHEMBL77524	0.74	5/20
SCHEMBL77165	0.70	5/20
Argatroban (SCHEMBL4375)	1.00	4/20
Benzamidine (SCHEMBL61379)	0.94	4/20
SCHEMBL77980	0.85	4/20

Clinical trials — most relevant to F2 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Efficacy and Safety of Prothromplex Total (Prothrombin Complex Concentrate) in Oral Anticoagulant Reversal	PHASE4	COMPLETED
Levonorgestrel-releasing Intrauterine System in Patients With Endometriosis	PHASE4	COMPLETED
International Normalized Ratio (INR) Normalization in Coumadin Associated Intracerebral Haemorrhage	PHASE4	COMPLETED
Coagulation in Cirrhosis	PHASE4	RECRUITING
PCC Treatment for Hemophilia Patients With Inhibitor（2022PCC-A）	PHASE4	RECRUITING
Citrate Anticoagulation vs. Heparin-Coated Dialyzers	PHASE3	COMPLETED
Point of Care Coagulation Testing in Patients Undergoing Major Surgery	PHASE3	COMPLETED
Effect of Hyperglycemia in PAI-1 Activity and the Relationship With Outcome in Severe Sepsis and Septic Shock	PHASE2/PHASE3	COMPLETED
Study of Fibrinogen Concentrate (Human) (FCH) to Control Bleeding During Complex Cardiovascular Surgery	PHASE3	COMPLETED
Prothrombin Complex Concentrate for Anticoagulant Reversal	PHASE3	COMPLETED
Evaluation of SCT800 in Prophylaxis Therapy on Previous Treated Patients With Severe Hemophilia A	PHASE3	COMPLETED
Preoperative Short Course Radiotherapy With Envafolimab, Endostatin and SOX Regimen in Locally Advanced Gastric	PHASE2	UNKNOWN
A Phase II Study to Evaluate the Safety and Efficacy of TQB2450 Injection in Relapsed or Refractory Classical Hodgkin's Lymphoma	PHASE2	UNKNOWN
Assessment of the Anti-inflammatory Effect of Heparin Infusion Versus Subcutaneous Injection in Septic Patients	PHASE2	COMPLETED
Effects of TNX-832 (Sunol cH36) in Subjects With Acute Lung Injury/Acute Respiratory Distress Syndrome	PHASE1	COMPLETED
IASO206 in Patients With Relapsed/Refractory Multiple Myeloma	EARLY_PHASE1	NOT_YET_RECRUITING
Coagulation After Intravenous Methylprednisolone Administration	nan	COMPLETED
Coagulation Activation in Patients With Pemphigus	nan	UNKNOWN
Chinese Community Inpatient Thromboembolism	nan	UNKNOWN
PROgnostic Value of MicroParticles and Markers of Hemostasis in TIA and Ischemic Stroke	nan	COMPLETED
Heparin Management During Cardiopulmonary Bypass in Children	nan	COMPLETED
Patients' Positions on Analgesic Efficacy of ESPB	nan	RECRUITING
Study of the Vascular Response to Percutaneous Coronary Intervention in Patients With Non-ST-elevation Acute Coronary Syndromes Using Intravascular Blood Sampling	nan	WITHDRAWN
Efficacy and Safety of Early Use PCC in Severe Trauma	nan	COMPLETED
Diffusion Tensor MRI to Distinguish Brain Tumor Recurrence From Radiation Necrosis	nan	COMPLETED
Thromboelastometry Guided DIC Prevention After Cesarean Section in Pregnant Women With Placenta Previa	nan	UNKNOWN
Mechanisms of Pro-Thrombosis in Diabetes Mellitus -- Ancillary to BARI 2D	nan	COMPLETED
Experimental Study of the Vascular Prosthesis Manufactured by Electrospinning	nan	COMPLETED
Risk Factors of Neonatal Thrombosis	nan	COMPLETED
Recombinant Activated Factor VII in the Management of Massive Bleeding in Hospital Universiti Sains Malaysia	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a F2 binder may also engage these)

Protein	Name	Similarity
Q5R537	—	1.000	Q5R537 →
P18292	—	1.000	P18292 →
P19221	—	1.000	P19221 →
P00735	—	1.000	P00735 →
Q19AZ8	—	1.000	Q19AZ8 →
O88947	—	0.994	O88947 →
P49150	—	0.994	P49150 →
P00743	—	0.993	P00743 →
F10	Coagulation factor X	0.992	landscape →
Q63207	—	0.991	Q63207 →
Q5E9Z2	—	0.990	Q5E9Z2 →
P31394	—	0.989	P31394 →
P33587	—	0.989	P33587 →
Q5R8J0	—	0.989	Q5R8J0 →
P04185	—	0.989	P04185 →
Q1L659	—	0.988	Q1L659 →
Q5E9P5	—	0.988	Q5E9P5 →
HABP2	Hyaluronan-binding protein 2	0.988	landscape →
F7	Coagulation factor VII	0.988	landscape →
P00745	—	0.988	P00745 →
A6MFK7	—	0.988	A6MFK7 →
Q6L711	—	0.988	Q6L711 →
HGF	Hepatocyte growth factor	0.987	landscape →
P29598	—	0.987	P29598 →
P11214	—	0.987	P11214 →
P98121	—	0.987	P98121 →
Q9GLP2	—	0.987	Q9GLP2 →
Q08048	—	0.987	Q08048 →
P19637	—	0.987	P19637 →
Q8K0D2	—	0.987	Q8K0D2 →